Related references
Note: Only part of the references are listed.The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo
Jayasree S. Nair et al.
CLINICAL CANCER RESEARCH (2009)
Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells
Tai-Lung Cha et al.
CLINICAL CANCER RESEARCH (2009)
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents
John R. Pollard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Clinical Experience with Aurora Kinase Inhibitors: A Review
David S. Boss et al.
ONCOLOGIST (2009)
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Yun Dai et al.
BLOOD (2008)
Molecular basis of drug resistance in Aurora kinases
Fiona Girdler et al.
CHEMISTRY & BIOLOGY (2008)
Aurora kinases as anticancer drug targets
Oliver Gautschi et al.
CLINICAL CANCER RESEARCH (2008)
Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth
Yvonne G. Lin et al.
CLINICAL CANCER RESEARCH (2008)
Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2008)
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
Yannick Arlot-Bonnemains et al.
ENDOCRINE-RELATED CANCER (2008)
Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152
Y. Tao et al.
ONCOGENE (2008)
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia
Xue-Fei Huang et al.
BLOOD (2008)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients
Barbara Vischioni et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function
Farid Gizatullin et al.
CANCER RESEARCH (2006)
Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma
M Kurai et al.
HUMAN PATHOLOGY (2005)
Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation
A Kanda et al.
ONCOGENE (2005)
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
EA Harrington et al.
NATURE MEDICINE (2004)
Aurora-kinase inhibitors as anticancer agents
N Keen et al.
NATURE REVIEWS CANCER (2004)
Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models
DW Zhang et al.
ONCOGENE (2004)
Share Paper
